Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis.
10.4070/kcj.2011.41.11.677
- Author:
Daisuke HACHINOHE
1
;
Myung Ho JEONG
;
Min Chol KIM
;
Kyung Hoon CHO
;
Khurshid AHMED
;
Seung Hwan HWANG
;
Min Goo LEE
;
Doo Sun SIM
;
Keun Ho PARK
;
Ju Han KIM
;
Young Joon HONG
;
Youngkeun AHN
;
Jung Chaee KANG
Author Information
1. The Heart Center of Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
- Publication Type:Case Report
- Keywords:
Drug-eluting stents;
Coronary restenosis;
Brachytherapy;
Angioplasty
- MeSH:
Angioplasty;
Angioplasty, Balloon;
Arteries;
Brachytherapy;
Coronary Angiography;
Coronary Restenosis;
Drug-Eluting Stents;
Follow-Up Studies;
Humans;
Middle Aged;
Myocardial Infarction;
Stents;
Thrombolytic Therapy;
Tissue Plasminogen Activator
- From:Korean Circulation Journal
2011;41(11):677-680
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 51-year-old man was admitted due to an acute anterior ST-segment elevation myocardial infarction. After thrombolytic therapy using recombinant tissue plasminogen activator, stent implantation was performed from the proximal left anterior descending artery (LAD) to the mid LAD using a bare-metal stent (BMS). Since then, the patient suffered five repeated episodes of in-stent restenosis (ISR). At the first ISR, he was treated with plain old balloon angioplasty (POBA). At the second ISR, he was treated with brachytherapy, and at the third ISR, he was treated with POBA and one more BMS distal to the previously implanted stent. At the forth, only POBA was performed, and finally, at the fifth ISR, a sirolimus-eluting stent was implanted. Following that, the patient remained asymptomatic and follow-up coronary angiography showed no ISR.
